Arimoclomol maleate NEW
| Price | $39 | $72 | $147 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-15 |
Product Details
| Product Name: Arimoclomol maleate | CAS No.: 289893-26-1 |
| Purity: 99.9% | Supply Ability: 10g |
| Release date: 2025/07/15 |
Product Introduction
Bioactivity
| Name | Arimoclomol maleate |
| Description | Arimoclomol maleate (BRX-220) (BRX-220) is a heat shock protein (HSP) co-inducer. |
| In vivo | Arimoclomol, administered for 5 d, has a protective effect against CCK-induced acute pancreatitis. Repeated CCK treatment results in the typical laboratory and morphological changes of experimentally induced pancreatitis. The pancreatic levels of HSP60 and HSP72 are significantly increased in the animals treated with Arimoclomol [1]. Arimoclomol is a co-inducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 250 mg/mL (581.60 mM), Sonication is recommended. |
| Keywords | ubiquitin | system | protein | proteasome | neurons | motor | misfolded | Inhibitor | inhibit | HSP | Heat shock proteins | co-inducer | clearance | BRX220 | BRX 220 | assemblies | Arimoclomol Maleate | Arimoclomol maleate | Arimoclomol | aggregation |
| Inhibitors Related | Ethoxyquin | SNX0723 | Tamoxifen | SNX2112 | Ganetespib | Teprenone | Elesclomol | Rifabutin | Palmitic acid | Paeoniflorin | Tamoxifen Citrate | 17-AEP-GA |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $117.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-10 | |
| $0.00/25KG |
VIP6Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2021-10-08 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $39.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY